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Endometrial cancer (EC) remains the most common malignancy of the female genital tract. The median age at diagnosis is
the sixth decade, with abnormal uterine bleeding at the presentation in 90% of the patients. Surgical treatment, including
complete hysterectomy, removal of remaining adnexal structures, and an appropriate surgical staging, represents the milestone
of curative therapy for patients with EC. Adjuvant therapy is necessary in patients at high risk of recurrence. Conservative
treatment approaches should be used in selected cases for women with a desire of fertility preservation. This review summarizes
the management of EC and discusses current controversies regarding the role of lymphadenectomy and radiotherapy in patients
with intermediate-risk tumors conﬁned to the uterus.
1.Introduction
Endometrial cancer (EC) remains the most common malig-
nancy of the female genital tract. It will develop in 2,6% of
women in the United States during their lifetime [1]. The
age-standardized death rate is 3.6 per 100,000 women and
the median age at diagnosis is the sixth decade, although 20
to 25% of cases will be diagnosed premenopausally [2, 3]
(Figure 1). It has been suggested that the overall distribution
of tumour stage and survival are similar for younger and
older women; however, women with stage I disease and
y o u n g e rt h a n4 5y e a r sa r em o r el i k e l yt oh a v el o w - g r a d e
disease localized to the endometrium [4, 5].
2. Risk Factors
The most important risk factors for EC are postmenopausal
status, excessive fat consumption, body mass index (BMI) of
25kg/m2 or more, nulliparity, anovulation, and unopposed
exogenous estrogen use. However, only half of patients
present with identiﬁable risk factors, while the other half
appear to be at low risk [6].
In particular, obesity, recently considered the most
common risk factor responsible of the development of all
endometrial carcinomas, increases the risk of EC through
a number of mechanisms that cause hormonal alteration
and consequently endometrial cell proliferation, apoptosis
inhibition, and angiogenesis promotion. In premenopausal
women, obesity causes insulin resistance, ovarian androgen
excess, anovulation, and chronic progesterone deﬁciency. On
the other hand, in postmenopausal women, the conversion
of androgens to estrogens is enhanced in peripheral fat
stores. Pregnancy, with intense placental production of
progestinsandgrandmultiparityprotectagainstEC,whereas
nulliparity increases the risk, especially when it is associated
with infertility. It is well established that oral contraceptives
with the addition of progesterone to estrogen, lower the
adverse eﬀects of estrogens on the endometrium and the
risk of EC [7]. Smoking appears to reduce the risk of EC
through its eﬀects on estrogen production and metabolism
[8]. Instead, the use of tamoxifen in patients with breast
cancer triples the risk of EC and also increases the chance
of developing benign endometrial polyps, hyperplasia, and
even carcinoma in some patients. However, the beneﬁcial
eﬀects of tamoxifen on breast cancer recurrence and its
association primarily with ECs of low grade and early
stage support its continued use in an appropriate patient
population [1].
While the incidence and mortality rates from several
other cancers have plateaued or decreased in the last decade,2 Obstetrics and Gynecology International
Figure 1: Adenocarcinoma of the uterine corpus.
rates for EC continue to rise [9]. This fact may be related
to an increased rate of advanced-stage cancers and high-risk
histologies including uterine papillary serous carcinoma
(UPSC), that is histologically similar to serous epithelial
ovarian carcinoma and represents approximately 10% of all
endometrial cancer [10].
Bokhman [11] proposed the existence of two categories
of endometrial carcinoma characterized by distinct micro-
scopic appearance, epidemiology, and clinical behaviour.
Type I carcinoma with an endometrioid histology, that
typically arises in relatively younger women with obesity,
hyperlipidemia, and signs of hyperestrogenism (endoge-
nous or exogenous); and type II carcinomas that include
poorly diﬀerentiated endometrioid, clear cell, and serous
histologies. They often arise in thinner, older women and
demonstrate no hormonal risk factors. Moreover type I
endometrial carcinomas are commonly diagnosed at an
early stage and have a favourable prognosis, often with
surgical treatment alone; recurrences are usually local (pelvis
being the most common site) and frequently curable
with tumor-directed radiotherapy. Alternatively, type II
endometrial carcinomas are more likely to present with
metastatic disease at diagnosis and carry a poorer prognosis
[12].
3.DiagnosticApproach
Abnormal uterine bleeding is present in 90% of patients with
EC. Therefore, any vaginal bleeding in a postmenopausal
woman warrants an initial evaluation for EC, that is found
approximately in 10% of patients with postmenopausal
bleeding (PMB) [1]. Because of this symptom, 75% of
ECs are diagnosed at an early stage. Atypical endometrial
hyperplasia (AEH) is felt to be a precursor of lesion and it
may progress, over time, to EC in 5% to 25% of patients.
In addition, AEH is associated with a coexisting EC in
approximately 20% of patients [13, 14].
Diagnostic approaches to the assessment of abnormal
uterine bleeding are divided into invasive and noninvasive
methods.
3.1. Invasive Methods
3.1.1. Dilatation and Curettage (D&C). Traditionally con-
sidered the standard for investigation of abnormal uterine
bleeding.
3.1.2. Endometrial Biopsy. A variety of instruments (the
Pipelle, the Pipette, the Tis-U-Trap and the Z-sampler) has
been developed over the last decade for using in the oﬃce
as alternatives to the expense, risk, and inconvenience of
fractional D&C. With the use of these devices, the sensitivity
for detecting endometrial cancer ranges from 67% to 96%.
3.1.3. Hysteroscopy and Directed Biopsy. Some consider this
methodasthestandardforthediagnosisofabnormaluterine
bleeding. However, a recent study of 373 patients which
retrospectively compared hysteroscopy and D&C, concluded
that hysteroscopy did not improve upon the sensitivity of
D&C in the detection of endometrial hyperplasia or carci-
noma. On the contrary, Clark et al. found that hysteroscopy
is highly accurate and useful in diagnosing, rather than
excluding, endometrial cancer in women with abnormal
uterine bleeding [15]. A recent study performed by Bedner
and Rzepka-Gorska compared the eﬀectiveness of D&C with
hysteroscopy and guided biopsy in perimenopausal women
at risk of endometrial hyperplasia or cancer. They found
that hysteroscopy with directed biopsy was more sensitive
than D&C for detecting all types of uterine lesions [16].
Several retrospective studies have found increased positive
peritoneal cytology in women who underwent hysteroscopy,
but recent studies have indicated that there is currently no
evidencetosuggestthatdiagnostichysteroscopyincreasesthe
risk ofmalignant cellsspreading into theperitonealcavity,or
worsens the prognosis in women with EC.
3.2. Noninvasive Methods
3.2.1. Ultrasonography. Two large studies of 930 women
and of 138 women reported experiences with transvaginal
ultrasound in women with postmenopausal bleeding. Both
studies used a biendometrial (double layer) thickness of four
m i l l i m e t r e sa sac u t - o ﬀ point. The sensitivity was 96% to
98% and the speciﬁcity was 36% to 68%. The false positive
rate was 44% to 56%. Thickness could not be measured in
3% to 4.7% but the reason for this was not stated. One of
the studies reported two cancers in patients with a thickness
less than 3.5mm, giving a false negative rate of two per 930
(0.2%) [2].
3.2.2. Endometrial Cytology. This is not felt to be useful
in diagnosis of EC, due to low accuracy and it will not
be discussed further. In a prospective study conducted by
Karlsson et al. [17], on 1168 women with PMB underwent to
transvaginal ultrasonography followed by uterine curettage,
the risk of endometrial abnormality was 6.1%, considering
a threshold of 5mm or less, with a sensitivity of 94%, a
speciﬁcity of 78%, a positive predictive value (PPV) of 69%,
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accuracy of 84%. With this threshold, it was determined
a risk of endometrial abnormalities of 6,1% (upper 95%
conﬁdencelevel of 8.5%) and ECs wereundetected. The high
NPV of this test lends itself well to excluding a diagnosis of
EC in patients who cannot undergo endometrial sampling.
However, it should be emphasized that the aforementioned
results are limited to patients with PMB. Screening for EC
using transvaginal ultrasonography alone in asymptomatic
postmenopausal women has a poor PPV (9%) and is not
recommended, whereas the combination of transvaginal
ultrasonography and endometrial biopsy has shown a sen-
sitivity of 100% [18].
Evaluation for systemic disease is typically limited to
chest radiography and laboratory evaluation performed in
preparation for surgery, but magnetic resonance imaging
(MRI), that is superior to computed tomography for visu-
alizing uterus and pelvic tissues [19], is recommended as
knowledge of extrauterine spread or cervix involvement
by tumor. On the other hand, baseline cancer antigen
levels can be useful, but they are not enough sensitive to
predict the status of disease. We recently showed [20] that
transvaginal sonography (TVS) when carried out by expert
hands shows a comparable accuracy to MRI in depicting
myometrial inﬁltration of endometrial carcinoma, thus we
recommend a combination of both techniques for detecting
an accurate myometrial invasion. In detection of subclinical
nodal disease, to deﬁne extent of disease, integrated PET/CT
imaging has been investigated by Montejo et al. and only
modest improvement was achieved over to conventional
imaging, with an overall sensitivity and speciﬁcity of 50%
and 86.7%, respectively [21].
4. Treatment of PrecursorLesions
Continuous stimulation of the endometrium by either
endogenous or exogenous estrogen is the most important
risk factor for endometrial hyperplasia and EC conse-
quently. The World Health Organization (WHO) classiﬁes
the endometrial hyperplasia in simple, a benign proliferation
of endometrial glands involving mild or moderate glandular
crowding (adenomatous hyperplasia) and complex, that is
characterized by back-to-back cellular crowding and an
irregular cellular outline. Both simple or complex hyperpla-
sia could be associated with cellular atypia. It can be subdi-
vided into mild atypia (nuclear enlargement and rounding
with evenly dispersed chromatin) or moderate atypia (larger
nuclear size, prominent nucleoli, and clumped chromatin).
Hyperplasia without atypia, either simple or complex, has
a low likelihood (1% and 3%, respectively) of progressing
to carcinoma. In contrast, atypical endometrial hyperplasia
is believed to be the direct precursor to endometrioid EC
[11, 12].
A recent investigation by The Gynecologic Oncology
Group (GOG) [22] found that from 19% to 62% of endome-
trial biopsy specimens interpreted as atypical endometrial
hyperplasia were associated with an invasive EC at hysterec-
tomy.Forthisreason,simpleandcomplexhyperplasiacanbe
treated with progestational therapy only, whereas hysterec-
tomy is mandatory for all patients with atypical hyperplasia.
Medroxyprogesteroneacetateormegestrolacetate,theagents
used in most retrospective studies to treat endometrial
hyperplasia without atypia, can be administered in either a
cyclic or continuous fashion.
Atypical hyperplasia regresses after treatment with pro-
gestins in 60% to 95% of patients [23]. However, because of
the high rate of frankly invasive EC in patients with atypical
hyperplasia [24] and the high risk of progression to EC, hys-
terectomyisthestandardtreatment,whileprogestinstherapy
should be reserved for those women who desire a fertility-
preserving management. Continuous administration of local
progestational agents via the levonorgestrel (LNG)-releasing
intrauterine device (IUD) has been evaluated as an alterna-
tive delivery mechanism in treating endometrial hyperplasia,
both with and without atypia. It has an eﬃcacy of 100% with
lasting results during a minimum of 5 years of follow-up,
althoughonlysmallnumbersofpatientswereincludedinthe
studies published to date [25].
The LNG-releasing IUD has also been evaluated as
an alternative to hysterectomy for women with low-grade,
presumed early-stage EC who are poor operative candidates.
Cure rates up to 75% have been reported [26]. The current
committee opinion from the American College of Obstetrics
and Gynecology acknowledges that larger studies are needed
to evaluate the eﬃcacy of noncontraceptive uses of LNG-
releasing IUDs before they can be recommended as a
treatment alternative for atypical endometrial hyperplasia or
low-grade EC. Follow-up endometrial biopsy or curettage is
performed every 3 to 6 months until regression to normal
endometrium or lesion progression occurs [27]. However,
well-designed randomized trials for an optimal endometrial
hyperplasia management are lacking, and guidelines for
follow-up are also unclear. If vaginal bleeding resumes,
another endometrial biopsy should be performed [28, 29].
5. Fertility-SparingTreatmentof
EndometrialCancer
Considering that patients with stage I disease and younger
than 45 years are more likely to have low-grade disease local-
ized to the endometrium [30], a conservative management
of uterine cancer has been advocated as a safe alternative for
those women with desire of childbearing. Anyway, there is
stillnoconsensusaboutwhichwillbetheoptimalprocedure.
We recently proposed an innovative method [31]t o
preserve fertility in young women with stage IA EC, based
on the hysteroscopic resection of the tumor followed by
hormone therapy regimen of megestrol acetate (160mg/day)
for six months, for consolidation. This methods consists
of a conservative resectoscopic treatment using a three-step
technique in which each step is characterized by a pathologic
analysis: (1) the removal of the tumor, (2) the removal of
the endometrium adjacent to the tumor, and (3) the removal
of the myometrium underlying the tumor. This technique,
under a close postsurgical follow-up, might represent a novel
therapeutic option. The results of transvaginal ultrasound
examination and diagnostic hysteroscopy with target biop-
sies at 3, 6, 9, and 12 months after surgery were negative4 Obstetrics and Gynecology International
for atypia or malignancy and four out of six patients (66%)
achieved childbearing.
Moreover successful hormone therapy as an option for
appropriately selected young women who desire to preserve
fertility, with early-stage low-grade endometrial cancer, has
been reported in small series [32, 33].
This conservative management of EC should not be
considered standard of care, and the dosage and duration of
treatment, selection criteria, and follow-up surveillance are
notestablisheddeﬁnitely.Ina2004meta-analysis,Ramirezet
al. reviewed the literature regarding hormonal treatment of
grade I EC, including 27 articles with a combined total of 81
patients. A variety of progestational agents were used, most
often medroxyprogesterone acetate or megestrol acetate.
It was observed an overall response rate of 77% (62/81),
the median time to regression was 12 weeks and among
responders the recurrence rate was 24% [34].
All recurrences occurred within 1 year of diagnosis and
all patients who remained disease free (76% of the initial
responders) required treatment with progesterone for only
1 month to achieve a response. Twenty patients achieved
pregnancy after treatment. The 23% (19/81) of patients of
the original cohort never responded to treatment, and only
68% had any documented follow-up endometrial sampling.
Today there is no clear consensus on the optimal follow-
up interval. However, appropriate patient selection and
exclusion criteria remain undeﬁned, so patients must be
counseled that failure to identify recurrence or extension
of disease during progestational treatment could lead to a
delay in deﬁnitive surgery and ultimately a compromised
prognosis [35].
On the other hand, progestational therapy can be used
successfully to treat patients with atypical hyperplasia and
well-diﬀerentiated presumed stage I EC while preserving
fertility.
6.SurgicalTreatment ofEndometrial Cancer
Surgical treatment, including complete hysterectomy, re-
moval of remaining adnexal structures, and appropriate
surgical staging represents the milestone of curative therapy
for patients with EC. Survival is heavily dependent on
surgical stage, which is determined adopting the classiﬁ-
cation recently revised by the International Federation of
Gynecology and Obstetrics (FIGO) in 2008 (Table 1).
Most women with endometrial cancer have disease
conﬁned to the uterus and they are usually managed with
extra-fascial or simple total hysterectomy with bilateral
salpingo-oophorectomy (BSO) either as a laparotomic or
laparoscopic procedure. Lymph node involvement is an
adverseprognosticfactor;itisinﬂuencedchieﬂybythedepth
of myometrial invasion and the tumor grade. Regarding
the role of lymphadenectomy in women with disease that
clinically seems to be conﬁned to the uterus, there has been
much debate. Although lymphadenectomy forms part of
the International Federation of Gynecology and Obstetrics
(FIGO) surgical staging system [28], evidence from a large
randomized controlled trial, A Study in the Treatment of
Table 1: Carcinoma of the corpus uteri (FIGO 2008).
Stage I∗ Tumour conﬁned to the corpus uteri.
IA∗ No or less than half myometrial invasion.
IB∗ More than half myometrial invasion.
Stage II∗ Tumour invades cervical stroma, but does not
extend beyond the uterus.∗∗
Stage III∗ Local and/or regional spread of the tumour.
IIIA∗ Tumor invades the serosa of the corpus uteri and/or
adnexae#.
IIIB∗ Vaginal and/or parametrial involvement#.
IIIC∗ Metastases to pelvic and/or para-aortic lymph
nodes#.
IIIC1∗ ( i )P o s i t i v ep e l v i cn o d e s
IIIC2∗ (ii) Positive paraortic lymphnodes with or
without positive pelvic lymphnodes.
Stage IV∗ Tumor invades bladder and/or bowel mucosa,
and/or distant metastases.
IVA∗ Tumor invasion of bladder and/or bowel mucosa.
IVB∗ Distant metastases, including intra-abdominal
metastases and/or inguinal lymph nodes.
∗Either G1, G2, or G3.
∗∗Endocervical glandular involvement only should be considered as Stage
I and no more as Stage II.
#Positive cytology has to be reported separately without changing the stage.
Endometrial Cancer (ASTEC), showed that this approach
does not provide therapeutic beneﬁt [29].
Panici et al. conducted a randomized clinical trial to
determine whether the addition of pelvic systemic lym-
phadenectomy to standard hysterectomy with bilateral
salpingo-oophorectomy improves overall and disease-free
survival. They found that signiﬁcantly it improved only
surgical staging and neither overall or disease-free survival
[36].
A comparison of other two important studies, GOG-
99 and Postoperative Radiation Therapy in EC (PORTEC),
seems to suggest that lymphadenectomy does not aﬀect
disease-related and recurrence-free survival in patients with
intermediate-risk tumors conﬁned to the uterus [7, 37].
However, 60% of the patients enrolled in the PORTEC trial
were actually grade 1 (thus their prognosis was even more
favourable) whereas doubts have been raised concerning the
adequacy of surgical staging performed in the GOG-99 trial.
When the EC presents a cervical extension (stage II
FIGO), a radical hysterectomy, with an extensive dissection
to expose the ureters and secure the uterine vessels at
the origin rather than at their entry into the uterus, may
be considered. This type of surgery allows to remove the
parametrial tissue and facilitates safe dissection of the blad-
der away from the uterus and cervix such that a signiﬁcant
cuﬀ of upper vagina can be removed [38]. Parametrial
metastasis does not form part of the FIGO staging system,
but their involvement is associated with a poor prognosis
[28].
Mariani et al. reported the results of 34 women with
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disease-free survival at 5 years was 100% for women who
had radical hysterectomy with histologically negative nodes
versus a 5-year disease-free survival rate of 73% for women
who received simple hysterectomy [39].
Boente also evaluated 202 patients with stage II disease,
reporting a 5-year survival for radical hysterectomy and
nodal dissection of 86% compared with 77% for simple
hysterectomy [40].
However, some questions about the adequacy of lym-
phadenectomy, like the minimum number of nodes to
remove, if the para-aortic nodes should be resected and if the
hystotype of endometrial cancer should determine the extent
of lymphadenectomy, remain still unclear.
A small number of women are found to have advanced
endometrial cancer at presentation thus, to date there are
no prospective randomized data available to aid general con-
sensus about an appropriate management of these patients.
The appropriate extent of surgery in this setting of patients
and the true value of radical surgery in advanced disease
are still not clear. Pliskow et al. published a retrospective
study of 41 women with clinical stage III and IV endometrial
cancer, and suggested that the extent of disease and tumour
bulk have greater prognostic value than histological subtype,
grading, or depth of myometrial invasion. Other recent
studies propose that the primary cytoreductive surgery for
advanced endometrial cancer oﬀers a survival beneﬁt as in
epithelial ovarian cancer [41, 42].
7. Radiotherapy
The role of adjuvant radiotherapy in EC remains contro-
versial. Early endometrial cancer with low-risk pathological
features can be successfully treated by surgery alone. Several
trials, which have mainly included women at intermediate
or high risk of recurrence in stage 1, have been shown
that postoperative radiotherapy is able to reduce the risk of
isolated local recurrence without improving recurrence-free
or overall survival. In particular the PORTEC and the GOG-
99 trial randomized patients with intermediate risk stage 1
showing that external pelvic radiotherapy (EBRT) improves
local control but does not substantially increase survival in
patients with EC conﬁned to the uterus, with or without
surgical staging [37, 43].
The ASTEC trial, randomizing patients with IC-IIA or
IA-IIAG3 or serous papillary/clear cell for lymphadenec-
tomy, did not show a survival beneﬁt for adjuvant radio-
therapy in women with intermediate- or high-risk early
stage EC. Thus, the use of postoperative radiotherapy should
be limited to patients with suﬃciently high-risk of local
recurrence based on known risk factors such as age ≥ 60,
grade 2-3, depth of myometrial invasion, and cervical and
lymphovascular space involvement. The PORTEC-2 trial,
which compared the eﬃcacy of brachytherapy (BRT) versus
EBRT in patients with intermediate- or high-risk early stage
EC, concluded that BRT is eﬀective as EBRT in preventive
vaginal recurrences with less toxicity. Therefore BRT should
be considered the standard for these patients. However, as in
the original PORTEC trial, surgical staging is not required,
raising questions on the generalizability of these data. In
fact, if an appropriate surgical staging is not performed,
the administration of pelvic RT could lead to overtreatment
of those patients who have negative lymph nodes and
undertreatment of those with positive pelvic lymphnodes
who eventually present disease in the para-aortic area.
Patients with advanced EC (stage IIB, III FIGO) should
be considered for adjuvant external beam radiotherapy that
would reduce local recurrence, with or without vaginal vault
brachytherapy [44].
Bruckman et al. reported a retrospective review on EC
patients treated with adjuvant pelvic RT and low-dose rate
vaginal brachytherapy. Patients with extrauterine disease
limited to the ovary or fallopian tube had signiﬁcantly
improvedrelapse-freesurvivalandoverallsurvivalcompared
with those patients with disease spread beyond the adnexa
to other pelvic structures. Women with extrauterine disease
limited to the adnexa experienced relapse-free survival rates
of 80% and overall survival rates of 80% compared with 15%
and40%,respectively,forthosepatientswithdiseasetoother
pelvic structures beyond the adnexa [45].
8. Chemotherapy in Postoperative Treatment of
EndometrialCancer
The use of chemotherapy for patients with locally advanced
or metastatic EC is becoming nowadays more common.
Platinum compounds, taxanes, and anthracyclines provide
the major eﬀective drug classes in the treatment of advanced
and recurrent EC, all producing response rates of 20%
to 30%. For patients able to tolerate aggressive therapy,
multiagent chemotherapy produces higher response rates
than single-agent therapy [46]. The most active regimen
tested in randomized trials is the triplet consisting of
cisplatin (50mg/m2), doxorubicin (45mg/m2), and pacli-
taxel (160mg/m2) ,am y e l o t o x i cr e g i m e n ,w h i c hr e q u i r e s
granulocyte growth factor support [47].
Carboplatin and paclitaxel are used frequently because
of their ease administration and promising phase 2 results.
The GOG is currently comparing cisplatin-doxorubicin-
paclitaxel chemotherapy to carboplatin-paclitaxel in a large
randomized trial of patients with metastatic disease (GOG-
209).
In a prospective study by the GOG in patients with
relapsed or metastatic EC, doxorubicin and cisplatin were
chosen to compare chemotherapy to radiotherapy [48].
All women with stage III or IV disease of any histology
and with less than 2cm of residual disease after maximal
surgical debulking were eligible for the trial. Patients were
randomized to whole abdominal radiotherapy or 8 cycles
of doxorubicin and cisplatin chemotherapy. Toxicity was
higher in the chemotherapy group; only 63% of women
completed all 8 cycles of chemotherapy. Patterns of failure
analysis revealed that the initial site of failure was within
the pelvis in 13% of patients who underwent irradiation
versus 18% of those who received chemotherapy. To further
improve the results of chemotherapy alone, the GOG-
184 study, required all patients to receive tumor-directed6 Obstetrics and Gynecology International
radiotherapy (pelvic irradiation with or without para-
aortic irradiation, depending on lymph node involvement)
followed by randomization to cisplatin and doxorubicin or
cisplatin, doxorubicin, and paclitaxel. This trial has been
completed and data are awaiting maturation. It is hoped that
the combination of chemotherapy and targeted radiotherapy
will improve on historical results.
An important trial coordinated by the European Orga-
nization for Research and Treatment of Cancer (EORTC)
was recently presented in abstract form at the annual
meeting of the American Society of Clinical Oncology [49].
Women with stage I to IIIA or IIIC (pelvic lymph nodes
only) disease who were at high risk (>50% myometrial
invasion, Grade 3 or DNA nonploidy, clear or serous
histology) were randomized to external pelvic radiotherapy
or combined chemoradiotherapy. During a 10-year period,
372 patients were enrolled, with a median follow-up of 3.5
years. The investigation was closed early because of slow
recruitment, and multiple chemotherapeutic regimens were
allowed in combination with radiotherapy. The hazard ratio
for progression-free survival was 0.58 for chemoradiation
(95% conﬁdence interval [CI], 0.34–0.99; P = .046). This
translates to an estimated absolute diﬀerence in 5-year
progression-free survival of 7% (from 75% [95% CI, 67%–
82%]to82%[95%CI,73%–88%]).TheongoingPORTEC-3
trial is also investigating whether chemoradiation is superior
to radiation alone [50]. Patients are randomized to receive
pelvic radiotherapy or pelvic radiotherapy with concurrent
cisplatin followed by adjuvant carboplatin and paclitaxel
chemotherapy. Because many patients with recurrent or
stage IV EC are elderly, have received prior pelvic radiother-
apy, or have limited hematologic reserve, chemotherapeutic
regimens are often limited by toxicity.
The possible role of adjuvant hormonal therapy for stage
I EC has also been investigated but currently the evidences
are still insuﬃcient [51]t or e a c ha n yc o n c l u s i o n .
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